Who is sponsoring NCT05028231?

NCT05028231 is sponsored by Tongji Hospital.

What drugs are being tested in NCT05028231?

Interventions in NCT05028231: Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy.

What condition does NCT05028231 study?

NCT05028231 studies Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapies.

Is NCT05028231 still recruiting?

NCT05028231 is currently status unknown. Last updated 31 August 2021.

Last reviewed 2021-08-31 · How we verify

NCT05028231: NICCE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study

Status unknown Last updated 31 August 2021

What this trial tests

trial testing Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy in Esophageal Squamous Cell Carcinoma in 46 participants. Status unknown.

Timeline

5 June 2021

Primary endpoint
31 December 2022

31 December 2024

Quick facts

Lead sponsor	Tongji Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	46
Start date	5 June 2021
Primary completion	31 December 2022
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy

Conditions studied

Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →
Neoadjuvant Therapies — all drugs for Neoadjuvant Therapies →

Sponsor

Tongji Hospital

Who can join

Adults 18 to 70, any sex, with Esophageal Squamous Cell Carcinoma or Neoadjuvant Therapies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (PD-1 / PD-L1) combined with chemotherapy for locally advanced thoracic esophageal squamous cellcarcinoma.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
Li Q, Liu T, Ding Z. · · 2022 · cited 43× · PMID 36569908 · DOI 10.3389/fimmu.2022.1051841
Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future.
Liu Y. · · 2023 · cited 16× · PMID 37753366 · DOI 10.3748/wjg.v29.i34.5020
Targeting esophageal carcinoma: molecular mechanisms and clinical studies.
Wang W, Ye L, Li H, Mao W, et al · · 2024 · cited 7× · PMID 39415846 · DOI 10.1002/mco2.782
From tumor microenvironment to emerging biomarkers: the reshaping of the esophageal squamous cell carcinoma tumor microenvironment by neoadjuvant chemotherapy combined with immunotherapy.
Qiu Z, Li Z, Liu X, Zhang R, et al · · 2024 · cited 6× · PMID 39703499 · DOI 10.3389/fimmu.2024.1478922
Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma.
Deng S, Wang Q, Li Y, Zhang R, et al · · 2025 · cited 2× · PMID 40531216 · DOI 10.1007/s00262-025-04099-9
Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma
Deng S, Wang Q, Li Y, Zhang R, et al · · 2025 · DOI 10.21203/rs.3.rs-6357846/v1

Verify or expand the search:

Other recruiting trials for Esophageal Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting

Other Tongji Hospital trials

Trials by the same sponsor.

NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05028231 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
Last refreshed: 31 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05028231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing